Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2012, Article ID 485376, 12 pages
http://dx.doi.org/10.1155/2012/485376
Review Article

Muscular Dystrophies at Different Ages: Metabolic and Endocrine Alterations

Laboratorio de Biología Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, IMSS, 06703 Ciudad México, DF, Mexico

Received 21 December 2011; Accepted 2 April 2012

Academic Editor: Huan Cai

Copyright © 2012 Oriana del Rocío Cruz Guzmán et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Dalkilic and L. M. Kunkel, “Muscular dystrophies: genes to pathogenesis,” Current Opinion in Genetics and Development, vol. 13, no. 3, pp. 231–238, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. T. A. Rando, “The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies,” Muscle and Nerve, vol. 24, no. 12, pp. 1575–1594, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Bushby, “Recent advances in paediatric muscular dystrophies,” Current Paediatrics, vol. 14, no. 3, pp. 214–222, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Motlagh, J. R. MacDonald, and M. A. Tarnopolsky, “Nutritional inadequacy in adults with muscular dystrophy,” Muscle and Nerve, vol. 31, no. 6, pp. 713–718, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Bianchi, D. Biggar, K. Bushby, A. D. Rogol, M. M. Rutter, and B. Tseng, “Endocrine aspects of duchenne muscular dystrophy,” Neuromuscular Disorders, vol. 21, no. 4, pp. 298–303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. G. Smith and G. E. O. Muscat, “Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 10, pp. 2047–2063, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Abdul-Ghani and R. A. Defronzo, “Pathogenesis of insulin resistance in skeletal muscle,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 476279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Watanabe, H. Hayasaki, T. Tamayama, and M. Shimada, “Histologic distribution of insulin and glucagon receptors,” Brazilian Journal of Medical and Biological Research, vol. 31, no. 2, pp. 243–256, 1998. View at Google Scholar · View at Scopus
  9. A. M. Borissova, T. I. Tankova, and D. J. Koev, “Insulin secretion, peripheral insulin sensitivity and insulin-receptor binding in subjects with different degrees of obesity,” Diabetes and Metabolism, vol. 30, no. 5, pp. 425–431, 2004. View at Google Scholar · View at Scopus
  10. A. Aartsma-Rus, J. C. T. Van Deutekom, I. F. Fokkema, G. J. B. Van Ommen, and J. T. Den Dunnen, “Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule,” Muscle and Nerve, vol. 34, no. 2, pp. 135–144, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Bushby, R. Finkel, D. J. Birnkrant et al., “Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management,” The Lancet Neurology, vol. 9, no. 1, pp. 77–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Bushby, J. Bourke, R. Bullock, M. Eagle, M. Gibson, and J. Quinby, “The multidisciplinary management of Duchenne muscular dystrophy,” Current Paediatrics, vol. 15, no. 4, pp. 292–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Gonzalez-Bermejo, F. Lofaso, L. Falaize et al., “Resting energy expenditure in Duchenne patients using home mechanical ventilation,” European Respiratory Journal, vol. 25, no. 4, pp. 682–687, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Finsterer and C. Stöllberger, “The heart in human dystrophinopathies,” Cardiology, vol. 99, no. 1, pp. 1–19, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Eagle, S. V. Baudouin, C. Chandler, D. R. Giddings, R. Bullock, and K. Bushby, “Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation,” Neuromuscular Disorders, vol. 12, no. 10, pp. 926–929, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Koening, A. H. Beggs, M. Moyer et al., “The molecular basis for Duchenne versus becker muscular dystrophy: correlation of severity with type of deletion,” American Journal of Human Genetics, vol. 45, no. 4, pp. 498–506, 1989. View at Google Scholar · View at Scopus
  17. K. M. D. Bushby and D. Gardner-Medwin, “The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy,” Journal of Neurology, vol. 240, pp. 98–104, 1993. View at Google Scholar
  18. G. Nigro, L. I. Comi, L. Politano, and R. J. I. Bain, “The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy,” International Journal of Cardiology, vol. 26, no. 3, pp. 271–277, 1990. View at Publisher · View at Google Scholar · View at Scopus
  19. A. H. Beggs, E. P. Hoffman, J. R. Snyder et al., “Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies,” American Journal of Human Genetics, vol. 49, no. 1, pp. 54–67, 1991. View at Google Scholar · View at Scopus
  20. G. Nigro, L. I. Comi, L. Politano, and R. J. I. Bain, “The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy,” International Journal of Cardiology, vol. 26, no. 3, pp. 271–277, 1990. View at Publisher · View at Google Scholar · View at Scopus
  21. A. E. H. Emery, “X-linked muscular dystrophy with early contractures and cardiomyopathy (Emery-Dreifuss type),” Clinical Genetics, vol. 32, no. 5, pp. 360–367, 1987. View at Google Scholar · View at Scopus
  22. A. Muchir and H. J. Worman, “Emery-Dreifuss muscular dystrophy,” Current Neurology and Neuroscience Reports, vol. 7, no. 1, pp. 78–83, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. L. P. Rowland, M. Fetell, and M. Olarte, “Emery-Dreifuss muscular dystrophy,” Annals of Neurology, vol. 5, no. 2, pp. 111–117, 1979. View at Google Scholar · View at Scopus
  24. H. M. Becane, G. Bonne, S. Varnous et al., “High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation,” Pacing and Clinical Electrophysiology, vol. 23, no. 11 I, pp. 1661–1666, 2000. View at Google Scholar · View at Scopus
  25. K. E. Davies and K. J. Nowak, “Molecular mechanisms of muscular dystrophies: old and new players,” Nature Reviews Molecular Cell Biology, vol. 7, no. 10, pp. 762–773, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. B. S. Emanuel, E. H. Zackai, and S. H. Tucker, “Further evidence for Xp21 location of Duchenne muscular dystrophy (DMD) locus: X;9 translocation in a female with DMD,” Journal of Medical Genetics, vol. 20, no. 6, pp. 461–463, 1983. View at Google Scholar · View at Scopus
  27. G. T. Carter, M. D. Weiss, J. R. Chamberlain et al., “Aging with muscular dystrophy: pathophysiology and clinical management,” Physical Medicine and Rehabilitation Clinics of North America, vol. 21, no. 2, pp. 429–450, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Ervasti, K. Ohlendieck, S. D. Kahl, M. G. Gaver, and K. P. Campbell, “Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle,” Nature, vol. 345, no. 6273, pp. 315–319, 1990. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Yoshida and E. Ozawa, “Glycoprotein complex anchoring dystrophin to sarcolemma,” The Journal of Biochemistry, vol. 108, no. 5, pp. 748–752, 1990. View at Google Scholar
  30. E. R. Barton, “Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle,” American Journal of Physiology, vol. 290, no. 2, pp. C411–C419, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Bonilla, C. E. Samitt, A. F. Miranda et al., “Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell suface,” Cell, vol. 54, no. 4, pp. 447–452, 1988. View at Google Scholar · View at Scopus
  32. Z. Ren, C. Zhou, Y. Xu, J. Deng, H. Zeng, and Y. Zeng, “Mutation and haplotype analysis for Duchenne muscular dystrophy by single cell multiple displacement amplification,” Molecular Human Reproduction, vol. 13, no. 6, pp. 431–436, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. D. J. Blake, A. Weir, S. E. Newey, and K. E. Davies, “Function and genetics of dystrophin and dystrophin-related proteins in muscle,” Physiological Reviews, vol. 82, no. 2, pp. 291–329, 2002. View at Google Scholar · View at Scopus
  34. G. Bonne, M. R. Di Barletta, S. Varnous et al., “Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy,” Nature Genetics, vol. 21, no. 3, pp. 285–288, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Bione, E. Maestrini, S. Rivella et al., “Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy,” Nature Genetics, vol. 8, no. 4, pp. 323–327, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. H. J. Worman and G. Bonne, “‘Laminopathies’: a wide spectrum of human diseases,” Experimental Cell Research, vol. 313, no. 10, pp. 2121–2133, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. K. L. Wydner, J. A. McNeil, F. Lin, H. J. Worman, and J. B. Lawrence, “Chromosomal assignment of human nuclear envelope protein genes LMNA, LMNB1, and LBR by fluorescence in situ hybridization,” Genomics, vol. 32, no. 3, pp. 474–478, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. U. Aebi, J. Cohn, L. Buhle, and L. Gerace, “The nuclear lamina is a meshwork of intermediate-type filaments,” Nature, vol. 323, no. 6088, pp. 560–564, 1986. View at Google Scholar · View at Scopus
  39. J. G. Tidball and M. Wehling-Henricks, “Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis,” Current Opinion in Rheumatology, vol. 17, no. 6, pp. 707–713, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. T. M. Al-Harbi, L. J. Bainbridge, M. J. McQueen, and M. A. Tarnopolsky, “Hypogonadism is common in men with myopathies,” Journal of Clinical Neuromuscular Disease, vol. 9, no. 4, pp. 397–401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. B. H. P. Nagel, W. Mortier, M. Elmlinger, H. A. Wollmann, K. Schmitt, and M. B. Ranke, “Short stature in Duchenne muscular dystrophy: a study of 34 patients,” Acta Paediatrica, vol. 88, no. 1, pp. 62–65, 1999. View at Google Scholar · View at Scopus
  42. A. C. Söderpalm, P. Magnusson, A. C. Åhlander et al., “Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy,” Neuromuscular Disorders, vol. 17, no. 11-12, pp. 919–928, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Sih, J. E. Morley, F. E. Kaiser, H. M. Perry, P. Patrick, and C. Ross, “Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 6, pp. 1661–1667, 1997. View at Google Scholar · View at Scopus
  44. S. T. Page, J. K. Amory, F. D. Bowman et al., “Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1502–1510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Merlini, C. Granata, A. Ballestrazzi et al., “Growth hormone evaluation in duchenne muscular dystrophy,” The Italian Journal of Neurological Sciences, vol. 9, no. 5, pp. 471–475, 1988. View at Publisher · View at Google Scholar · View at Scopus
  46. G. R. Frank and R. E. Smith, “Effective growth hormone therapy in a growth hormone deficient patient with Duchenne muscular dystropy without evidence of acceleration of the dystrophic process,” Journal of Pediatric Endocrinology and Metabolism, vol. 14, no. 2, pp. 211–214, 2001. View at Google Scholar · View at Scopus
  47. D. G. Leung, E. L. Germain-Lee, B. E. Denger, and K. R. Wagner, “Report on the second endocrine aspects of duchenne muscular dystrophy conference December 1-2, 2010, Baltimore, Maryland, USA,” Neuromuscular Disorders, vol. 21, no. 8, pp. 594–601, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. D. E. McNeil, C. Davis, D. Jillapalli, S. Targum, A. Durmowicz, and T. R. Coté, “Duchenne muscular dystrophy: drug development and regulatory considerations,” Muscle and Nerve, vol. 41, no. 6, pp. 740–745, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. J. V. Chakkalakal, J. Thompson, R. J. Parks, and B. J. Jasmin, “Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies,” FASEB Journal, vol. 19, no. 8, pp. 880–891, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Q. Zhou, H. Q. Xie, S. Z. Zhang, and Z. M. Yang, “Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead,” Chinese Medical Journal, vol. 119, no. 16, pp. 1381–1391, 2006. View at Google Scholar · View at Scopus
  51. H. G. Radley, A. De Luca, G. S. Lynch, and M. D. Grounds, “Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 3, pp. 469–477, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Zatz, R. T. B. Betti, J. M. Opitz, and J. F. Reynolds, “Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five years follow-up,” American Journal of Medical Genetics, vol. 10, no. 3, pp. 301–304, 1981. View at Google Scholar
  53. R. D. Griffiths and R. H. T. Edwards, “A new chart for weight control in Duchenne muscular dystrophy,” Archives of Disease in Childhood, vol. 63, no. 10, pp. 1256–1258, 1988. View at Google Scholar · View at Scopus
  54. T. N. Willig, L. Carlier, M. Legrand, H. Riviere, and J. Navarro, “Nutritional assessment in Duchenne muscular dystrophy,” Developmental Medicine and Child Neurology, vol. 35, no. 12, pp. 1074–1082, 1993. View at Google Scholar · View at Scopus
  55. M. Zanardi, A. Tagliabue, S. Orcesi, A. Berardinelli, C. Uggetti, and A. Pichiecchio, “Body composition with dual energy x-ray absorptiometry in Duchenne muscular dystrophy: correlation of lean body mass with muscle function,” Muscle Nerve, vol. 19, no. 6, pp. 777–779, 2003. View at Google Scholar
  56. L. Martigne, J. Salleron, M. Mayer et al., “Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit,” British Journal of Nutrition, vol. 105, no. 10, pp. 1486–1491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. Z. E. Davidson and H. Truby, “A review of nutrition in Duchenne muscular dystrophy,” Journal of Human Nutrition and Dietetics, vol. 22, no. 5, pp. 383–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. R. R. Wolfe, “Control of muscle protein breakdown: effects of activity and nutritional states,” International Journal of Sport Nutrition, vol. 11, pp. S164–S169, 2001. View at Google Scholar · View at Scopus
  59. O. Borrelli, G. Salvia, V. Mancini et al., “Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy,” American Journal of Gastroenterology, vol. 100, no. 3, pp. 695–702, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Shimizu-Fujiwara, H. Komaki, E. Nakagawa et al., “Decreased resting energy expenditure in patients with Duchenne muscular dystrophy,” Brain and Development, vol. 34, no. 3, pp. 206–212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. M. R. Güell, M. Avendano, J. Fraser, and R. Goldstein, “Pulmonary and nonpulmonary alterations in Duchenne muscular dystrophy,” Archivos de Bronconeumologia, vol. 43, no. 10, pp. 557–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Pane, I. Vasta, S. Messina et al., “Feeding problems and weight gain in Duchenne muscular dystrophy,” European Journal of Paediatric Neurology, vol. 10, no. 5-6, pp. 231–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. S. E. Barlow and W. H. Dietz, “Obesity evaluation and treatment: expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services,” Pediatrics, vol. 102, no. 3, p. E29, 1998. View at Google Scholar · View at Scopus
  64. F. Lopez-Jimenez and W. R. Miranda, “Diagnosing obesity: beyond BMI,” American Medical Association Journal of Ethics, vol. 12, no. 4, pp. 292–298, 2010. View at Google Scholar
  65. E. Mok, G. Letellier, J. M. Cuisset, A. Denjean, F. Gottrand, and R. Hankard, “Assessing change in body composition in children with Duchenne muscular dystrophy: anthropometry and bioelectrical impedance analysis versus dual-energy X-ray absorptiometry,” Clinical Nutrition, vol. 29, no. 5, pp. 633–638, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Kanda, Y. Fujii, K. Takahashi, and T. Fujita, “Dual-energy X-ray absorptiometry in neuromuscular diseases,” Muscle and Nerve, vol. 17, no. 4, pp. 431–435, 1994. View at Google Scholar · View at Scopus
  67. E. Mok, L. Béghin, P. Gachon et al., “Estimating body composition in children with Duchenne muscular dystrophy: comparison of bioelectrical impedance analysis and skinfold-thickness measurement,” American Journal of Clinical Nutrition, vol. 83, no. 1, pp. 65–69, 2006. View at Google Scholar · View at Scopus
  68. J. Drefus, G. Schapira, F. Schapira, and J. Demos, “Activites enzymatiques du muscle humain: recherches sur la bichimie comparee de l’homme normal et myopathique et du rat,” Clinica Chimica Acta, vol. 1, no. 5, pp. 434–449, 1956. View at Google Scholar
  69. D. A. Ellis, “Intermediary metabolism of muscle in Duchenne muscular dystrophy,” British Medical Bulletin, vol. 36, no. 2, pp. 165–171, 1980. View at Google Scholar · View at Scopus
  70. U. Sharma, S. Atri, M. C. Sharma, C. Sarkar, and N. R. Jagannathan, “Skeletal muscle metabolism in Duchenne muscular dystrophy (DMD): an in-vitro proton NMR spectroscopy study,” Magnetic Resonance Imaging, vol. 21, no. 2, pp. 145–153, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Ibrahimi, A. Bonen, W. D. Blinn et al., “Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin,” Journal of Biological Chemistry, vol. 274, no. 38, pp. 26761–26766, 1999. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Nishio, H. Wada, T. Matsuo et al., “Glucose, free fatty acid and ketone body metabolism in Duchenne muscular dystrophy,” Brain and Development, vol. 12, no. 4, pp. 390–402, 1990. View at Google Scholar · View at Scopus
  73. G. R. Freidenberg and J. M. Olefsky, “Dissociation of insulin resistance and decreased insulin receptor binding in Duchenne muscular dystrophy,” Journal of Clinical Endocrinology and Metabolism, vol. 60, no. 2, pp. 320–327, 1985. View at Google Scholar · View at Scopus
  74. R. DeFronzo, D. Deibert, and R. Hendler, “Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes,” Journal of Clinical Investigation, vol. 63, no. 5, pp. 939–946, 1979. View at Google Scholar · View at Scopus
  75. B. Mokri and A. G. Engel, “Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber,” Neurology, vol. 25, no. 12, pp. 1111–1120, 1975. View at Google Scholar · View at Scopus
  76. E. Yechiel and Y. Barenholz, “Relationships between membrane lipid composition and biological properties of rat myocytes,” Journal of Biological Chemistry, vol. 260, no. 16, pp. 9123–9131, 1985. View at Google Scholar · View at Scopus
  77. T. J. Hsieh, C. K. Wang, H. Y. Chuang, Y. J. Jong, C. W. Li, and G. C. Liu, “In Vivo proton magnetic resonance spectroscopy assessment for muscle metabolism in neuromuscular diseases,” Journal of Pediatrics, vol. 151, no. 3, pp. 319–321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. I. Illa, C. Serrano, E. Gallardo et al., “Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype,” Annals of Neurology, vol. 49, pp. 130–134, 2001. View at Google Scholar
  79. L. Broglio, M. Tentorio, M. S. Cotelli et al., “Limb-girdle muscular dystrophy-associated protein diseases,” Neurologist, vol. 16, no. 6, pp. 340–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. A. A. Amato and R. J. Barohn, “Inclusion body myositis: old and new concepts,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 11, pp. 1186–1193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. P. Reilich, N. Schramm, B. Schoser et al., “Facioscapulohumeral muscular dystrophy presenting with unusual phenotypes and atypical morphological features of vacuolar myopathy,” Journal of Neurology, vol. 257, no. 7, pp. 1108–1118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Brais, “Oculopharyngeal muscular dystrophy: a polyalanine myopathy.,” Current Neurology and Neuroscience Reports, vol. 9, no. 1, pp. 76–82, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Reilich, N. Schramm, B. Schoser et al., “Facioscapulohumeral muscular dystrophy presenting with unusual phenotypes and atypical morphological features of vacuolar myopathy,” Journal of Neurology, vol. 257, no. 7, pp. 1108–1118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. D. H. Cho and S. J. Tapscott, “Myotonic dystrophy: emerging mechanisms for DM1 and DM2,” Biochimica et Biophysica Acta, vol. 1772, no. 2, pp. 195–204, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. P. S. H. Harper, Myotonic Dystrophy, W.B. Saunders, London, UK, 3rd edition, 2001.
  86. J. D. Brook, M. E. McCurrach, H. G. Harley et al., “Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member,” Cell, vol. 68, no. 4, pp. 799–808, 1992. View at Google Scholar · View at Scopus
  87. C. E. M. De Die-Smulders, C. J. Höweler, C. Thijs et al., “Age and causes of death in adult-onset myotonic dystrophy,” Brain, vol. 121, no. 8, pp. 1557–1563, 1998. View at Publisher · View at Google Scholar · View at Scopus
  88. G. Sicot, F. Gourdon, and M. Gomes, “Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges,” Human Molecular Genetics, vol. 20, no. 2, pp. 116–123, 2011. View at Google Scholar
  89. M. A. Hauser, S. K. Horrigan, P. Salmikangas et al., “Myotilin is mutated in limb girdle muscular dystrophy 1A,” Human Molecular Genetics, vol. 9, no. 14, pp. 2141–2147, 2000. View at Google Scholar · View at Scopus
  90. C. T. Rocha and E. P. Hoffman, “Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies,” Current Neurology and Neuroscience Reports, vol. 10, no. 4, pp. 267–276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. G. Antonini, A. Clemenzi, E. Bucci et al., “Hypogonadism in DM1 and its relationship to erectile dysfunction,” Journal of Neurology, vol. 258, no. 7, pp. 1247–1253, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. J. A. Vazquez, J. A. Pinies, P. Martul, A. De los Rios, S. Gatzambide, and M. A. Busturia, “Hypothalamic-pituitary-testicular function in 70 patients with myotonin dystrophy,” Journal of Endocrinological Investigation, vol. 13, no. 5, pp. 375–379, 1990. View at Google Scholar · View at Scopus
  93. J. M. Gomez Saez, J. M. Fernandez Real, M. Fernandez Castaner, M. A. Navarro Moreno, J. A. Martinez Matos, and J. Soler Ramon, “Study on growth hormone and insulin secretion in myotonic dystrophy,” Clinical Investigator, vol. 72, no. 7, pp. 508–511, 1994. View at Google Scholar · View at Scopus
  94. I. Mastrogiacomo, G. Bonanni, E. Menegazzo et al., “Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy,” Italian Journal of Neurological Sciences, vol. 17, no. 1, pp. 59–65, 1996. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Mahadevan, C. Tsilfidis, L. Sabourin et al., “Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene,” Science, vol. 255, no. 5049, pp. 1253–1255, 1992. View at Google Scholar · View at Scopus
  96. J. A. Vazquez, J. A. Pinies, P. Martul, A. De los Rios, S. Gatzambide, and M. A. Busturia, “Hypothalamic-pituitary-testicular function in 70 patients with myotonin dystrophy,” Journal of Endocrinological Investigation, vol. 13, no. 5, pp. 375–379, 1990. View at Google Scholar · View at Scopus
  97. I. Mastrogiacomo, G. Bonanni, E. Menegazzo et al., “Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy,” Italian Journal of Neurological Sciences, vol. 17, no. 1, pp. 59–65, 1996. View at Publisher · View at Google Scholar · View at Scopus
  98. R. C. Griggs, D. Halliday, W. Kingston, and R. T. Moxley, “Effect of testosterone on muscle protein synthesis in myotonic dystrophy,” Annals of Neurology, vol. 20, no. 5, pp. 590–596, 1986. View at Google Scholar · View at Scopus
  99. G. Antonini, A. Clemenzi, E. Bucci et al., “Hypogonadism in DM1 and its relationship to erectile dysfunction,” Journal of Neurology, vol. 258, no. 7, pp. 1247–1253, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. V. Chaudhry, T. Umapathi, and W. J. Ravich, “Neuromuscular diseases and disorders of the alimentary system,” Muscle and Nerve, vol. 25, no. 6, pp. 768–784, 2002. View at Publisher · View at Google Scholar · View at Scopus
  101. T. Matsumura, H. Iwahashi, T. Funahashi et al., “A cross-sectional study for glucose intolerance of myotonic dystrophy,” Journal of the Neurological Sciences, vol. 276, no. 1-2, pp. 60–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. P. Kaminsky, M. Poussel, L. Pruna, J. Deibener, B. Chenuel, and B. Brembilla-Perrot, “Organ dysfunction and muscular disability in myotonic dystrophy type 1,” Medicine, vol. 90, no. 4, pp. 262–268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Aitkens, D. D. Kilmer, N. C. Wright, and M. A. McCrory, “Metabolic syndrome in neuromuscular disease,” Archives of Physical Medicine and Rehabilitation, vol. 86, no. 5, pp. 1030–1036, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. P. Björntorp and R. Rosmond, “The metabolic syndrome—a neuroendocrine disorder?” British Journal of Nutrition, vol. 83, no. 1, pp. S49–S57, 2000. View at Google Scholar · View at Scopus
  105. R. S. Savkur, A. V. Philips, and T. A. Cooper, “Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy,” Nature Genetics, vol. 29, no. 1, pp. 40–47, 2001. View at Publisher · View at Google Scholar · View at Scopus
  106. D. E. Moller, A. Yokota, J. F. Caro, and J. S. Flier, “Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man,” Molecular Endocrinology, vol. 3, no. 8, pp. 1263–1269, 1989. View at Google Scholar · View at Scopus
  107. J. C. Walsh, J. R. Turtle, S. Miller, and J. G. Mcleod, “Abnormalities of insulin secretion in dystrophia myotonica,” Brain, vol. 93, no. 4, pp. 731–742, 1970. View at Publisher · View at Google Scholar · View at Scopus
  108. G. Perseghin, A. Caumo, C. Arcelloni et al., “Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy,” Diabetes Care, vol. 26, no. 7, pp. 2112–2118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. F. Bertuzzi, A. M. Davalli, R. Nano et al., “Mechanisms of coordination of Ca2+ signals in pancreatic islet cells,” Diabetes, vol. 48, no. 10, pp. 1971–1978, 1999. View at Publisher · View at Google Scholar · View at Scopus